Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.
Adding bevacizumab to capecitabine did not improve survival for patients with stage III or high-risk stage II disease.
Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has...
A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks.
The U.S. Food and Drug Administration (FDA) has approved bevacizumab, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by bevacizumab alone, for the treatment of patients with...
Adding bevacizumab to perioperative chemotherapy failed to improve survival.
What if your family's DNA could become the blueprint for your very own precise and personalized treatment for colorectal cancer? Or, better yet, what if it could be used to help doctors screen you earlier for the disease, before it has a chance to strike?
A liquid biopsy option for potential colorectal cancer patients. Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90%, but only approximately four out of 10 CRC cases [...]
Colorectal cancer is the second leading cause of cancer death for men and women in the United States according to the American Cancer Society.
The Ohio State University have trialed a colorectal cancer screening initiative for relatives of colorectal cancer patients. The results are promising.
Colorectal cancer is one of several cancers with known genetic risk factors. Because these known factors can be identified through genetic testing, it’s important to understand your risks and to discuss them with your healthcare provider. The following are three hereditary factors that can increase your risk for colorectal cancer: People with a personal or […] The post Genetic Factors and ...
This video examines results of the CHARTA trial, which tested first-line FOLFOX plus bevacizumab with or without irinotecan in patients with advanced colorectal cancer.
To the Editor The comprehensive review by Dr Lieberman and colleagues addressed evolving issues in the field of colorectal cancer screening. However, I take issue with the brief discussion of serrated polyps and their effect on the practice of colorectal cancer screening.
Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, and therefore more accessible screening tests are urgently needed...
When diagnosed early, before cancer has spread, the relative five-year survival rate for colorectal cancer (CRC) is 90%, but only...
Approximately 140,000 people are diagnosed with colorectal cancer in the U.S. each year. March is Colorectal Cancer Awareness Month.
(American Cancer Society) Despite dramatic reductions in overall colorectal cancer incidence and mortality, striking disparities by age, race, and tumor subsite remain
Adding bevacizumab to cisplatin and etoposide improved progression-free survival, but not overall survival, the primary outcome.
Patients with colorectal cancer may be able to lower the risk of the disease worsening and improve their chances of survival with moderate daily exercise, according to new research by investigators at Dana-Farber Cancer Institute. The results of the research contradict the widespread belief that, because the prognosis for patients with metastatic cancer is often poor, […] The post Metastati...
Genentech announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone, for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Women are said to...
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial–mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against...
Colorectal cancer rates have risen dramatically among Generation Xers and millenials; researcher warns that repeal of the Affordable Care Act is 'very concerning' for cancer diagnosis. Medscape Medical News
March is Colorectal Cancer Awareness Month, which the American Institute of Cancer Research is marking with a news release headlined “6 Steps to Prevent Nearly Half of Colorectal Cancer Cases.” The recommendations are said to be “research-based” but that term appears to be used loosely. Here’s why. What’s wrong with issuing sensible lifestyle recommendations? The […]